Urticarial vasculitis

Gu, Stephanie L.; Jorizzo, Joseph L.

doi:10.1016/j.ijwd.2021.01.021

Cited by 38 publications

(49 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Urticarial vasculitis is an uncommon clinic‐pathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions and LCV. 48 Three cases were published in association with COVID‐19 vaccination. Two after the first dose of Moderna vaccine.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

Abdelmaksoud

Wollina

Temiz

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Currently the most powerful tool in combating the COVID‐19 pandemic is vaccination against SARS‐CoV‐2. A growing percentage of the world's population is being vaccinated. Various vaccines are worldwide on the market. Several adverse reactions have been reported as a part of post‐marketing surveillance of COVID‐19 vaccines. Among the possible adverse events, cutaneous vasculitis has occasionally been reported. We present a narrative review on cutaneous vasculitis related to COVID‐19‐vaccination to summarize clinical findings, histopathology, treatment and outcome. We searched for “COVID vaccine”, “COVID vaccination” AND “cutaneous vasculitis” in PUBMED. Articles in English have been selected, from inception to December 2021, and analyzed for patient's characteristics, type of vaccine, time of appearance of cutaneous vasculitis and clinico‐histopathologic type. Treatment and outcome have also been considered in this narrative review. Two new unpublished cases of ours were added. Cutaneous vasculitis is a rare adverse event to COVID‐19 vaccination. It has been observed with mRNA and adenovirus‐vector vaccines. IgA vasculitis, lymphocytic and ANCA‐associated vasculitis, leukocytoclastic and urticarial vasculitis have been reported. This adverse event can occur after first or second shot. Most cases run a mild to moderate course. Cornerstone of medical treatment are systemic corticosteroids. Complete remission could be achieved in most patients. Vasculitis may not be considered as a contraindication of vaccination, being uncommonly reported and shows a favorable prognosis. The benefit of the vaccination remains high especially for immunocompromised patients. COVID‐vaccine induced vasculitis is important in the differential diagnosis of purpuric and vasculitis disorders.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Three cases were published in association with COVID‐19 vaccination. Two after the first dose of Moderna vaccine 34,38,48 …”

Section: Resultsmentioning

confidence: 99%

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

Abdelmaksoud

Wollina

Temiz

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Additionally, joint involvement is mainly found in hypocomplementemic urticarial vasculitis rather than in normocomplementemic urticarial vasculitis. 7 Besides, although not all viral infections are investigated, these diagnoses are unlikely, as they are usually accompanied by other features characteristic of the specific viral infections (eg, transaminitis for viral hepatitis and pharyngitis for Epstein-Barr virus infection).…”

Section: Discussionmentioning

confidence: 99%

“…Serology for hepatitis viruses indicated an inactive carrier state for hepatitis I). [5][6][7] The diagnosis prompted the prescription of high-dose oral corticosteroid treatment (prednisolone 1 mg/kg/day), colchicine (1.2 mg/day), antihistamines, and a moderate-potency topical steroid. Given the rapid improvement of the patient's…”

Section: Case Reportmentioning

confidence: 99%

Serum sickness-like reaction following an administration of the first dose of inactivated COVID19 vaccine

et al. 2022

View full text Add to dashboard Cite

“…Therefore, in response to requests from patients and their families, we acceded to their entreaties "to try anything that might help" by discussing the potential risks and possible benefit of several untested, unproven treatments and anecdotal reports that have been published recently. This includes the published discussions of experience with, and rationale for, dapsone in the COVID-19 disease [4][5][6][7][8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

Benefits of Using Dapsone in Patients Hospitalized with COVID-19

Kanwar¹,

Khattak²,

Balentine³

et al. 2022

Vaccines

View full text Add to dashboard Cite

Since the start of the SARS-CoV-2 pandemic, refractory and relentless hypoxia as a consequence of exuberant lung inflammation and parenchymal damage remains the main cause of death. We have earlier reported results of the addition of dapsone in this population to the standard of care. We now report a further chart review of discharge outcomes among patients hospitalized for COVID-19. The 2 × 2 table analysis showed a lower risk of death or discharge to LTAC (Long term acute care) (RR = 0.52, 95% CI: 0.32 to 0.84) and a higher chance of discharge home (RR = 2.7, 95% CI: 1.2 to 5.9) among patients receiving dapsone compared to those receiving the usual standard of care. A larger, blinded randomized trial should be carried out urgently to determine if dapsone indeed improves outcomes in COVID-19.

show abstract

Urticarial vasculitis

Cited by 38 publications

References 60 publications

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

SARS‐CoV‐2 vaccination‐induced cutaneous vasculitis: Report of two new cases and literature review

Serum sickness-like reaction following an administration of the first dose of inactivated COVID19 vaccine

Benefits of Using Dapsone in Patients Hospitalized with COVID-19

Contact Info

Product

Resources

About